In an exchange filing, Emcure said the agreement will be effective from April 1, 2026. Under the arrangement, the company will distribute Roche’s established brands in the nephrology and transplant segment across India.
The portfolio covered under the agreement includes CellCept, an immunosuppressant used in organ transplants, as well as Mircera and Neorecormon, therapies indicated for anaemia in chronic kidney disease (CKD). Mircera is a long-acting erythropoiesis-stimulating agent (ESA) with dosing once every two to four weeks.
Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, said the partnership aligns with the company’s focus on improving outcomes in anaemia and renal care. “Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India,” he added.Also read: Emcure Pharma Q3 Results: Strong operating performance but stock gives up gains
Rajji Mehdwan, Managing Director and CEO of Roche India & Neighbouring Markets, said, “Through Emcure’s strong distribution, on network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche’s long-standing innovations in transplant and CKD care.”
Emcure said the collaboration is aimed at expanding patient access to therapies in chronic kidney disease, anaemia management and transplant care.
The company, along with its subsidiaries, has an existing presence in anaemia management and nephrology, and said Roche’s portfolio complements its current offerings.
Emcure Pharmaceuticals, headquartered in Pune, is engaged in the development, manufacturing and global marketing of pharmaceutical products and operates in more than 70 countries. Roche India is a subsidiary of the Switzerland-based Roche Group.
Shares of the company ended marginally lower – close to the previous session’s closing price – at ₹1,454.20 on Monday. The stock has gained 52.03% in the last 12 months.
